The Russian government has permitted two more Russian pharmaceutical companies — PSK Pharma and Promomed Rus — to use patents for semaglutide without authorization from Danish drugmaker Novo Nordisk, which holds the rights to the drug.
Specifically, according to Directive No. 3931-r dated December 20, 2025, and “in connection with an extreme necessity related to safeguarding the life and health of citizens,” PSK Pharma LLC has been permitted to use inventions protected by five Russian patents belonging to Novo Nordisk until December 31, 2026. The permission was granted without the rightsholder’s consent “for the purpose of supplying the population of the Russian Federation with medications containing the INN semaglutide.”
A similar permission, according to Directive No. 3885-r dated December 19, was issued to Promomed Rus.
Both documents came into force on January 1, 2026. Previously, Geropharm received such permission.
Novo Nordisk originally developed the drug Ozempic (semaglutide) for the treatment of type 2 diabetes, but it is now widely used as a weight-loss treatment. Until 2023, Ozempic was the only semaglutide-based drug on the Russian market. After Novo Nordisk halted supplies of Ozempic to Russia, locally produced analogues began to appear in the country.